Latest ABOS news

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Zacks Investment Research · Mon, 21 Sep 2026 13:40:52 -0400

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Seeking Alpha · Wed, 16 Sep 2026 19:01:37 -0400

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

GlobeNewsWire · Thu, 10 Sep 2026 16:00:00 -0400

NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · Thu, 10 Sep 2026 12:27:14 -0400

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewsWire · Wed, 02 Sep 2026 16:00:00 -0400

NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Seeking Alpha · Wed, 12 Aug 2026 10:57:10 -0400

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Acumen Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · Wed, 12 Aug 2026 09:03:59 -0400

Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.

Market information is provided for research and visualization and is not investment advice.